The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Airbus Joins Air India A320 Altitude Drop Probe 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
